[RAAS and angiogenesis].
Angiotensin II(Ang II) is a potent vasoconstrictor and exerts inflammation and cell proliferation, thereby promoting angiogenesis. There are two major subtypes of Ang II receptors, AT1R and AT2R. AT1R mediates proangiogenic effect through enhancement of inflammation and leukocytes infiltration, while AT2R mediates antiangiogenic effect through regulation of apoptosis. Recently, Ang IV receptor was identified as insulin-regulated aminopeptidase, however, its roles in angiogenesis remain unknown. Although AT1R antagonist, ARB, has been proved its protective effects for the heart, kidney, and brain under many pathological conditions, it remains unknown whether long-term administration of ARB could be beneficial for therapeutic angiogenesis in patients with ischemic heart disease or peripheral artery disease. Further investigations are required.